Policy directives have pinpointed the next five years as a battleground for capital competition, with large-scale commercialization and rapid industry growth sweeping the healthcare AI sector. On November 4, five national departments, including the National Health Commission, issued the "Implementation Opinions on Promoting and Standardizing 'AI + Healthcare' Applications." This document aligns with the State Council's August 2025 "Opinions on Deepening the 'AI+' Initiative," accelerating AI adoption in healthcare and driving commercialization. The guidelines emphasize eight key areas: AI + grassroots applications, AI + clinical diagnosis, AI + patient services, and AI + public health, among others. By 2027, specialized clinical vertical models and intelligent applications are expected to emerge, with AI-assisted diagnostics and decision-making widely adopted in medical institutions. By 2030, AI-assisted grassroots diagnostics should achieve near-universal coverage, while secondary hospitals and above will broadly implement AI-powered medical imaging and clinical decision support.

As a pioneer in healthcare AI innovation, XUNFEIHEALTH (02506) has already launched a diverse AI product matrix for grassroots clinics, hospitals, and patients. At the 2025 iFLYTEK Global 1024 Developer Conference, the company unveiled a leap in its Spark Medical Model capabilities, officially releasing the Smart Doctor Assistant Hospital Edition 1.0 for tiered hospitals and upgrading the Xiaoyi AI platform, garnering significant attention. With first-mover advantages, XUNFEIHEALTH continues to invest in R&D, building an unassailable technological moat. Clearly, policy tailwinds and growing market demand position the company to lead the industry into a golden era of healthcare AI over the next five years.

**At the Forefront of Technology: Building the Strongest "Tech Foundation"** XUNFEIHEALTH’s AI advancements are backed by its robust R&D team and the leadership of its parent company, iFLYTEK, in AI. Overcoming domestic computing challenges early on, the company has consistently led in technological innovation. Since 2023, its Spark Medical Model has leveraged homegrown computing power and large-scale applications to refine core medical capabilities, maintaining industry leadership. The latest upgrade achieves breakthroughs in medical Q&A, language comprehension, documentation, diagnostics, and multimodal interaction, outperforming GPT-5 (high) and DeepSeek V3.2-Exp.

Empowered by high-quality medical data and evidence-based reasoning, XUNFEIHEALTH’s Smart Doctor Assistant now supports 2,500 diagnoses with 98% first-visit accuracy, adding features like TCM-assisted diagnostics. In complex hospital settings, the model achieves 93.1% diagnostic accuracy in outpatient scenarios—surpassing junior and even senior doctors—while excelling in inpatient care with specialist-level performance.

The company also launched upgraded AI products, including Smart Doctor Assistant Hospital Edition 1.0 for tiered hospitals and an enhanced Xiaoyi AI Health Assistant for patients, offering personalized health management.

**Policy-Driven Growth and Market Leadership** According to Frost & Sullivan, China’s healthcare AI sector grew at a 33.8% CAGR from 2019–2023 and is projected to expand at 43% CAGR through 2033, reaching RMB 315.7 billion. The new guidelines will accelerate adoption across sectors. XUNFEIHEALTH’s AI diagnostic and health assistant suites, targeting government (G), business (B), and consumer (C) segments, are poised to capture early policy-driven growth in G and B markets before scaling in C.

With its first-mover edge, relentless R&D, and leading AI product ecosystem, XUNFEIHEALTH is well-positioned to dominate market share. Beyond China, the company eyes global expansion, leveraging its "homegrown computing foundation" and "open ecosystem strategy" to build a worldwide healthcare AI network. Its Hong Kong IPO and the international rollout of Spark Medical Model V2.5 signal this ambition.

As the first港股-listed healthcare AI model stock, XUNFEIHEALTH is set to sustain high growth and command premium valuation in the coming five years.